We’re very excited that the life science and clinical research community will now have access to new biomarker tests through V-PLEX, said Jacob Wohlstadter, President and CEO
Rockville, MD (PRWEB) September 11, 2013
There is a significant unmet need for accurate and precise biomarker tests for clinical trials, drug development and medical research. V-PLEX simultaneously measures multiple biomarkers using assays that are grouped into panels for optimal and consistent performance. The V-PLEX immunoassay menu focuses on emerging biomarkers that are generally not available on traditional diagnostics platforms, giving researchers access to new types of tests.
“We’re very excited that the life science and clinical research community will now have access to new biomarker tests through V-PLEX,” said Jacob Wohlstadter, President and CEO. “The lack of validated tests for biomarkers has challenged pharmaceutical companies and been a major limitation for important medical research. Together with our recently launched QuickPlex™ SQ 120 instrument, V-PLEX offers unprecedented access to high-quality immunoassays in a flexible and affordable format.”
Validated tests enable long-term programs like clinical trials and epidemiological studies by providing sustainable, reliable measurements of clinically significant markers. These tests have defined, rigorous specifications for analytical performance, and each new lot passes strict requirements before release. Results from validated tests are viewed with greater confidence and are often required for regulatory approvals.
“The practical implications of V-PLEX are significant, particularly for laboratories and CROs that run biomarker tests as their primary business” said Dr. James Wilbur, General Manager. “In the absence of available tests, these laboratories must bear the burden of developing their own tests and conducting formal validations, which is simply unaffordable for many markers. With V-PLEX, these laboratories can now offer a wide menu of biomarkers in a fully-validated format, and, through the use of V-PLEX panels, reduce their labor, costs and sample consumption even further.”
V-PLEX immunoassays, using MSD’s proprietary electrochemiluminescence (ECL) MULTI-ARRAY® technology, are developed under rigorous design control and are fully validated according to “Fit for Purpose” principles. They are compatible with either MSD’s SECTOR® or QuickPlex instrument lines. The initial menu of V-PLEX immunoassays includes the most important cytokines, chemokines, and Alzheimer’s disease biomarkers.
For more information on V-PLEX immunoassays, call Customer Service at 1-240-314-2795; email email@example.com; or visit http://www.mesoscale.com/V-PLEX.